Comments
Jubilant Life Sciences today said its wholly-owned subsidiary has received approval from the Australian health regulator Therapeutic Goods Administration (TGA) for Lyophilised kit for the preparation of injection used for lung scan.
“Jubilant Pharma, through one of its units Jubilant DraxImage Inc Montreal Canada (JDI), has received approval from TGA, Australia, for Lyophilised kit for preparation of Technetium 99m Macro-Aggregated Albumin (MAA) injection,” Jubilant Life Sciences said in a BSE filing.
It further said: “MAA provides accurate scans to assess lung perfusion and rule out pulmonary embolism with low radiation exposure. JDI is the leading supplier of MAA in the US and has approval in four other countries, including Canada, Columbia, Hong Kong and Israel.”
The Australian MAA product is expected to be launched as part of JDI’s larger commitment to investing in the growth and robust sustainability of nuclear medicine globally and cater to the needs of suspected pulmonary embolism patients, the company added.
Shares of Jubilant Life Sciences were trading 0.64 per cent lower at Rs 643.65 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.